netFormulary NHS
Pan Mersey
Area Prescribing Committee
 Formulary Chapter 10: Musculoskeletal and joint diseases - Full Section

Coronavirus guidance

Guidance to support primary care prescribers and pharmacists is available from the MLCSU Coronavirus guidance resource page. Links are provided to national resources and regional documents produced by MLCSU, RDTC, and SPS for use by Pan Mersey APC, LSCMMG, and GMMMG.

The list of resources will be updated as new material becomes available so please check back regularly for updates.

The Pan Mersey APC supports the use of COVID-specific guidance issued by NICE, and NHS England and NHS Improvement. During the COVID pandemic this will supersede any APC advice.

Musculoskeletal and joint disease

Review date: October 2022

Non-formulary drugs: Any drug or formulation not listed in the formulary is deemed to be non-formulary.

Off-label use: Drugs are included in the formulary for their licensed indications – where inclusion of off-label use is considered to be included in the formulary this is specifically stated in the formulary entry for the drug N.B. also see Paediatrics note below.

Paediatrics: Drugs are included in the formulary for paediatric use for their BNF for Children recommended indications (indicated by symbol View childrens BNF) which may be off-label, unless otherwise stated. All drugs are deemed to have the same RAG status as they have for adults unless stated otherwise.

NHS England Specialised Commissioning
Drugs carrying the NHS England logo are commissioned by them. Links to key documents, national programmes of care, and clinical reference groups are found below.

NHSE NHS England Specialised Commissioning: Key documents

NHSE NHS England Specialised Commissioning: National programmes of care and clinical reference groups

 Useful Links

10.01 Drugs used in rheumatic diseases and gout
Rheumatoid arthritis and other inflammatory disorders
Osteoarthritis and soft-tissue disorders
10.01.01 Non-steroidal anti-inflammatory drugs
10.01.02 Corticosteroids Systemic corticosteroids Local corticosteroid injections
10.01.03 Drugs which suppress the rheumatic disease process
Drugs affecting the immune response
Cytokine modulators
10.01.04 Gout and cytotoxic-induced hyperuricaemia
Acute attacks of gout
Long-term control of gout
Hyperuricaemia associated with cytotoxic drugs
10.01.05 Other drugs for rheumatic diseases
10.02 Drugs used in neuromuscular disorders
10.02.01 Drugs which enhance neuromuscular transmission
Immunosuppressant therapy
Acetylcholine-release enhancers
10.02.02 Skeletal muscle relaxants
Other muscle relaxants
Nocturnal leg cramps
10.03 Drugs for the treatment of soft-tissue disorders and topical pain relief
10.03.01 Enzymes
10.03.02 Rubefacients, topical NSAIDs, capsaicin, and poultices
Topical NSAIDs and counter-irritants
10.04 Autologous chondrocyte implantation